Penile Squamous Cell Carcinoma

Comprehensive Executive Overview: Penile Squamous Cell Carcinoma (PSCC)

Penile Squamous Cell Carcinoma (PSCC) is a rare but highly significant malignancy arising from the squamous epithelium of the penis. Classified under ICD-10 code C60.9, this condition represents approximately 95% of all primary penile malignancies. While relatively uncommon in developed nations, its incidence remains a public health concern in specific regions of the world, often linked to socioeconomic factors, hygiene practices, and human papillomavirus (HPV) prevalence.

As a clinical entity, PSCC is characterized by its potential for rapid local invasion and regional lymphatic metastasis. Early detection is the single most critical factor in determining patient morbidity and long-term survival. Because the disease often carries a social stigma that leads to delayed patient presentation, clinical awareness and high-index suspicion are paramount for urologists and primary care providers alike.

Pathophysiology, Etiology, and Risk Factors

The oncogenesis of penile cancer is a multifactorial process. The transition from healthy squamous epithelium to invasive carcinoma typically follows a pathway of chronic inflammation or viral-induced cellular transformation.

The Role of HPV

High-risk Human Papillomavirus (HPV) genotypes, particularly HPV 16 and 18, are implicated in approximately 40% to 50% of PSCC cases. The viral E6 and E7 oncoproteins interfere with tumor suppressor proteins p53 and retinoblastoma (pRb), leading to uncontrolled cell cycle progression and genomic instability.

Chronic Inflammation and Phimosis

In cases where HPV is not the primary driver, chronic inflammation—often secondary to phimosis (the inability to retract the foreskin)—plays a major role. Phimosis facilitates the accumulation of smegma, which acts as a chronic irritant, promoting epithelial hyperplasia and eventual malignant transformation.

Key Risk Factors

• Phimosis: The single most significant non-viral risk factor.
• Tobacco Use: Smoking is strongly correlated with an increased risk of developing PSCC due to the accumulation of carcinogens in the urine.
• Lichen Sclerosus (Balanitis Xerotica Obliterans): A chronic inflammatory dermatosis that can lead to scarring and malignancy.
• Age: The incidence peaks in men between the ages of 50 and 70.
• Immunosuppression: Patients with HIV/AIDS are at a significantly higher risk.

Signs, Symptoms, and Clinical Presentation

The clinical presentation of PSCC is often subtle, frequently masquerading as benign dermatological conditions. Patients must be educated to report any persistent penile lesion that fails to resolve with standard topical therapy.

Standard Diagnostic Evaluation & Workup

Diagnostic accuracy is achieved through a systematic approach combining physical examination, imaging, and definitive histopathological analysis.

Clinical Examination

A thorough physical exam must include careful palpation of the primary tumor to assess the depth of invasion and a meticulous examination of the bilateral inguinal regions to detect lymph node involvement.

Definitive Diagnosis: The Biopsy

The gold standard for diagnosis is a wedge or punch biopsy of the lesion. Histopathological examination identifies the grade and depth of invasion, which are essential for staging.

Imaging Modalities

• Penile MRI: Used to determine the depth of invasion, particularly if the tumor involves the corpora cavernosa.
• CT/PET-CT: Utilized for staging and identifying distant metastasis or enlarged pelvic/retroperitoneal lymph nodes.
• Dynamic Sentinel Lymph Node Biopsy (DSNB): A crucial procedure in patients with clinically negative inguinal nodes (cN0) to identify microscopic metastasis.

Therapeutic Interventions

Treatment for PSCC is stratified based on the tumor stage and grade. The overarching philosophy is "organ-sparing" when oncologically safe, balanced against the necessity of wide excision for higher-stage disease.

Surgical Management

• Conservative/Organ-Sparing Surgery: For low-stage tumors (Tis, Ta, T1a), wide local excision with clear margins is the standard of care. This may involve circumcision or glans resurfacing.
• Partial or Total Penectomy: Reserved for larger, invasive tumors where clear margins cannot be achieved with conservative surgery.
• Lymph Node Management: Inguinal lymph node dissection (ILND) is the definitive treatment for metastatic nodal disease. Due to the high morbidity of traditional ILND, robotic-assisted or video-endoscopic techniques are increasingly utilized.

Pharmacotherapy and Adjuvant Care

• Topical Therapy: Imiquimod or 5-fluorouracil (5-FU) may be used for carcinoma in situ (CIS).
• Chemotherapy: Neoadjuvant chemotherapy (e.g., cisplatin, paclitaxel, ifosfamide) is often used in cases of bulky regional nodal disease to downstage the tumor prior to surgery.
• Radiotherapy: Generally reserved for primary tumors in patients who refuse surgery or for palliative care in advanced systemic disease.

Prognosis and Follow-Up

Prognosis is primarily dependent on the presence of inguinal lymph node metastasis. Patients with node-negative disease have a 5-year survival rate of approximately 85–90%, whereas this drops significantly if pelvic nodes are involved. Rigorous lifelong follow-up is mandatory, with frequency decreasing over time: every 3 months for the first 2 years, then every 6 months up to 5 years.

Frequently Asked Questions (FAQ)

1. Is penile cancer caused by poor hygiene?
While poor hygiene contributes to the accumulation of smegma and chronic inflammation—increasing the risk—it is not the sole cause. HPV infection and smoking are also major independent risk factors.

2. Can circumcision prevent penile cancer?
Yes, neonatal circumcision is associated with a significantly lower risk of developing PSCC, as it eliminates the risk of phimosis and the accumulation of irritants under the foreskin.

3. What is the survival rate for PSCC?
Survival depends on the stage at diagnosis. Early-stage detection leads to excellent outcomes, while late-stage cases involving lymph node spread have a poorer prognosis.

4. Does penile cancer always require amputation?
No. If detected early, "organ-sparing" surgeries, such as wide local excision or glans resurfacing, can often preserve the functional penis.

5. How do I know if a spot on my penis is cancer?
Any persistent sore, ulcer, or lump that does not heal within 2–4 weeks should be evaluated by a urologist, regardless of whether it is painful.

6. Is penile cancer contagious?
The cancer itself is not contagious. However, the Human Papillomavirus (HPV) that causes many cases of penile cancer is sexually transmitted.

7. What is the role of the sentinel lymph node biopsy?
It helps identify if cancer cells have spread to the lymph nodes even when the nodes feel normal during a physical exam.

8. Can I still have sexual function after treatment?
Many patients maintain sexual function, especially after conservative, organ-sparing procedures. Even after partial penectomy, many men report satisfactory sexual quality of life.

9. Is chemotherapy always needed?
No. Chemotherapy is typically reserved for advanced cases, specifically those with confirmed regional lymph node metastasis or systemic spread.

10. How often should I get checked after treatment?
Post-treatment surveillance is intense, usually every 3 months for the first two years, as this is the period of highest risk for recurrence.